NCT06117540View on ClinicalTrials.gov

A Study of WX390 in Patients With Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2026

Conditions
Solid Tumor
Interventions
DRUG

WX390

WX390 tablet, 1.1 mg once a day

Trial Locations (1)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY